CompletedNCT03834766
Extended-Release Amphetamine for Adults With ADHD
About this title
Read the official source — NCT03834766Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Bradenton and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 6, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 130
- Sponsor
- Tris Pharma, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT03834766
- Official title
Show the full official title
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBradenton · Maitland · Las Vegas
Questions about this study
Who is behind this study?
The study sponsor is Tris Pharma, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including AMPH ER Tab 5, 10, 15 and 20 mg and AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg.
Who was this study for?
Listed age limits: 18 years to 60 years.
